Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
about
Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsMultiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Pharmacology of anticoagulants used in the treatment of venous thromboembolismVKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarkerA cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Considerations when prescribing trimethoprim-sulfamethoxazole.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.Drug interactions with warfarin enantiomers--a different perspective.Comparison of a new microcrystalline dicoumarol preparation with warfarin under routine treatment conditionsDo single enantiomers have something special to offer?Progress in clinical pharmacology over the last 20 years.Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsMechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Clinical pharmacokinetics of ranolazine.The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarinsPharmacogenomic progress in individualized dosing of key drugs for cancer patients.Warfarin-antiretroviral interactions.Drug interactions with antiretrovirals and warfarin.Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke.Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know.Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal.Novel anticoagulants for stroke prevention in patients with atrial fibrillation.Personalized medicine: elusive dream or imminent reality?Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method.The plasma elimination of the enantiomers of phenprocoumon in man.Stereoselectivity: an issue of significant importance in clinical pharmacology.Species-dependent stereospecific serum protein binding of the oral anticoagulant drug phenprocoumon.On chiral drug action.CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Warfarin and warfarin-alcohol levels in anticoagulated patients.Development and registration of chiral drugs.Thrombosis and the pharmacology of antithrombotic agents.The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
P2860
Q24678775-5801A82E-BBB2-4EE3-B009-FA38A8C95E9BQ27334876-FC87F7E5-A544-47CD-AC21-7C441EE00BF3Q28078967-302C30C1-A241-44F0-BC50-ABEB9D088BADQ28476502-8091024F-CDCA-4BD3-81E8-535E6DFD23D6Q30568150-9177DC6B-417D-451F-88A2-F15C26294C83Q33517162-46E76C5F-A7A8-4B8E-BF83-7BC354E15748Q34223201-BAD039C4-3B6F-4616-9E86-EE4319A5F3B9Q34252907-66D80D04-EDAD-46A3-A195-933B2F7E70ABQ34346399-A729864D-5CDB-4DFB-9085-914512F06B56Q34348637-3FA95D0D-AECF-49A4-A622-72F56A21DEA5Q34447317-7F2D84B6-C45E-4DC3-8CB9-BCAD662E1589Q34517283-D25C2297-A9D5-4A59-8D18-0C8CB5D875B4Q34517745-33AD1C6D-7267-4267-991F-6C8E7426C87EQ34982614-FA867B10-E66B-4565-9088-3D00457BF4E8Q35130802-D25C3AAE-BA02-47A0-B2FC-305A01224271Q35826093-6A6E0E92-2B2B-4A0B-8F58-EAB8A5D6A3B8Q36040772-959B0951-1F25-418F-9421-B8E5D33A4AC3Q36460838-D8A2499B-AD68-4A1F-AE63-572EE7B1707CQ36762797-583B3E26-25E3-4A19-B27E-786E43F54085Q37019459-E592111C-9F5E-44C7-A419-48D85267FC0BQ37378994-3D555A3F-4E5C-429C-974F-11FAB0EBF2C3Q37386503-F4FB69E8-571F-4DF4-92AF-033D34FD56FCQ37679935-3AD0FB80-2F93-46FE-9E00-586D20021BEAQ37801000-564127AF-D657-4169-96E0-D8216C25D29DQ37863679-D032DFEA-D48A-486C-B7FA-7E1C1E14BAE2Q38197728-A703C1B9-42F7-44E4-9359-4C09EB65AB69Q38212962-3CAEE7B5-FE21-4094-9235-8DB0BA0C08AEQ38448112-BA12509B-D8BC-41E5-B82C-6D0E0C803A33Q38734321-E62E060F-D3F4-43C3-8E18-63607145ACD0Q38830008-E085BE7F-9341-44D6-8D9C-FAAC798D1C0BQ38858766-A96D2E0B-4532-4279-84E6-1711CA0F9094Q39099133-6B56A4EE-E752-4F0F-97D6-FAFA430B091DQ39529348-4331A393-5825-4B56-B934-D051CBD2A4CAQ39644462-C08D9400-7BB4-482E-9EE1-2F427D6ED46DQ40076893-35CFB838-953A-4FDA-8913-C7C408F8F4D9Q40174813-14D0042E-D8EE-4DBF-B38D-159BA2D40F2CQ40636276-16A91FB9-4B73-4E54-A6DD-03A96730ED3FQ40903080-0A135DBE-9019-47D6-A59B-3E9F09537DACQ40938710-0EF9CB59-4622-4D7D-950C-437484109812Q41118521-335E73EF-4D62-4DCB-8C6F-F8C50CF87584
P2860
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年学术文章
@wuu
1974年学术文章
@zh
1974年学术文章
@zh-cn
1974年学术文章
@zh-hans
1974年学术文章
@zh-my
1974年学术文章
@zh-sg
1974年學術文章
@yue
1974年學術文章
@zh-hant
name
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@en
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@nl
type
label
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@en
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@en
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@nl
P2093
P356
P1476
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
@en
P2093
P304
P356
10.1002/CPT1974154424
P407
P577
1974-04-01T00:00:00Z